PIONEER 6: Cardiovascular Safety for the Tablet

Name: PIONEER 6: Cardiovascular Safety for the Tablet
Creator: Ruth Calder
Published: 2026-11-07

Last verified November 2026 · Phase 3a · Finished; published June 2019 · NCT02692716 ↗

By Ruth Calder · Enforcement Editor

Editorially reviewed. Not medical advice · How we verify contentLast reviewed November 2026

Oral semaglutide is the same molecule delivered through a much less efficient route: only a small fraction is absorbed, which is why Rybelsus requires the fasting window and why the milligram doses look so different from the injectable. The obvious question is whether that variability in absorption undermines the benefit the injection demonstrated. PIONEER 6 was designed to rule out harm rather than to prove benefit, and it did so, with the event counts pointing in the favorable direction.

Enrollment: 3,183
Duration: Run until enough events accumulated rather than to a fixed date, giving a median 15.9 months, far shorter than the multi-year trials it gets compared against
Drug: Oral semaglutide (once daily, up to 14 mg)
Population: Adults with type 2 diabetes and an HbA1c of 7.0% or higher, entering either at 50 and over with established cardiovascular disease or reduced kidney function, or at 60 and over with risk factors alone. 84.7% arrived with established disease. Average age 66, 31.6% women, average BMI 32.3, average HbA1c 8.2%, and nearly 15 years since diagnosis. 61% were on insulin, a sign of advanced disease rather than a newly diagnosed population.

The Rybelsus drug page covers the drug itself: its dosing, cost and side effects.

Primary endpoint

Cardiac death, a nonfatal heart attack, or a nonfatal stroke — whichever came first

Treatment arm

61 of 1,591 (3.8%)

Comparator

76 of 1,592 (4.8%)

Treatment difference: Hazard ratio 0.79 (95% CI 0.57–1.11); P<0.001 for non-inferiority; P=0.17 for superiority

The trial cleared the bar it was built to clear: the tablet is not cardiovascularly worse than placebo. The 21% reduction in the point estimate is encouraging but did not reach significance (P=0.17 for superiority). The confidence interval crossed 1, and this trial was sized for safety on a short timeline, not to prove benefit.

Secondary endpoints

PIONEER 6 secondary endpoints, treatment against comparator. Last verified November 2026.
Endpoint	Treatment	Comparator	Difference
Death from a cardiac cause A 51% reduction, the most eye-catching number on this page and the one most often quoted without its condition attached. The trial's own pre-set testing order had already stopped by this point, so this is a nominal finding rather than an established one, and it rests on 15 deaths against 30.	15 of 1,591 (0.9%)	30 of 1,592 (1.9%)	Hazard ratio 0.49 (95% CI 0.27–0.92)
Heart attacks that were not fatal Numerically higher on the drug, on small numbers and a wide interval. The pattern differs from the injectable semaglutide trial, but there is not much to read into it either way.	37 of 1,591 (2.3%)	31 of 1,592 (1.9%)	Hazard ratio 1.18 (95% CI 0.73–1.90)
Strokes that were not fatal Slightly fewer, with too few events over 16 months to say more.	12 of 1,591 (0.8%)	16 of 1,592 (1.0%)	Hazard ratio 0.74 (95% CI 0.35–1.57)
Death from any cause at all The most contested figure in this trial: 23 deaths against 45, a 49% reduction. It is large, with a confidence interval excluding 1, yet formally uninterpretable under the trial's own testing plan, on small numbers over a short follow-up. Treat anyone quoting it as proof this tablet saves lives with real caution.	23 of 1,591 (1.4%)	45 of 1,592 (2.8%)	Hazard ratio 0.51 (95% CI 0.31–0.84)
A wider count adding heart-failure and unstable-angina admissions Pointing the same way as the main result and not significant, with heart-failure admissions much the same in both arms. Counts are per the trial's ClinicalTrials.gov results.	83 of 1,591 (5.2%)	100 of 1,592 (6.3%)	Hazard ratio 0.82 (95% CI 0.61–1.10)
Three-month average blood sugar at the end of treatment A full point of improvement at the 14 mg dose. The tablet does the glucose job, in a trial that was not built to measure that.	−1.0 percentage points	−0.3 percentage points	A gap of about 0.7 percentage points between the observed means, per the trial's ClinicalTrials.gov results
Weight change About 4 kg. Meaningful, and nowhere near the weight-management doses of injected semaglutide. This is the diabetes tablet in an older, insulin-treated population.	−4.2 kg	−0.8 kg	Estimated treatment difference −3.4 kg
Confirmed low blood sugar No excess from the drug itself. What causes lows here is the insulin that 61% of participants were already taking, and the sulfonylureas that many others were on.	Rates broadly similar between arms (semaglutide did not increase hypoglycemia on its own)	Baseline rate from background insulin and sulfonylureas	No clinically meaningful imbalance reported
Stopped the drug early over a side effect Roughly double placebo, concentrated while the dose was being raised. This has been a persistent real-world problem for the oral form specifically, and it belongs in any decision between a tablet and an injection.	11.6%	6.5% (104/1,592)	Higher on oral semaglutide, driven by gastrointestinal events during titration

Adverse events

PIONEER 6 adverse events, rate on treatment against rate on comparator. Last verified November 2026.
Event	Treatment rate	Comparator rate
Any serious adverse event Lower on the drug than on placebo, mostly because a high-risk population had fewer cardiac events on it.	18.9% (301/1,591)	22.5% (358/1,592)
Stopped the drug over a side effect 11.6% against 6.5%, peaking in the four to eight weeks of dose escalation, and driven by stomach and bowel problems.	11.6%	6.5% (104/1,592)
Nausea The most common complaint, mostly mild to moderate and early. The label puts it at roughly one in five patients at the 14 mg dose.	Higher on oral semaglutide than placebo (consistent with the PIONEER program; specific incidence not the headline endpoint in the safety publication)	Lower (placebo rate similar to other GLP-1 CVOT placebo arms)
Pancreatitis reported as a serious adverse event One against three on placebo, per the trial's ClinicalTrials.gov results. No signal of increased risk.	1 report (0.1%)	3 reports (0.2%)
Sudden kidney injury reported as a serious adverse event Much the same in both arms, per the trial's ClinicalTrials.gov results. Vomiting and diarrhea during titration can still dehydrate, which is a practical reason to keep fluids up while the dose is climbing.	0.8% (13/1,591)	0.9% (14/1,591)
Diabetic eye disease getting worse No significant excess here, unlike the injectable semaglutide trial, which found a clear one. The label still advises eye monitoring if you have retinopathy and your blood sugar is falling fast, because the mechanism is the speed of improvement, not the formulation.	7.1% (113/1,591)	6.3% (101/1,592)
Cancers of any kind Balanced between the arms, but 16 months is far too short for cancer risk to declare itself, so this is not reassurance about long-term use.	Rates balanced between arms over the trial period	Rates balanced between arms over the trial period

Subgroup analyses

People who arrived with established cardiovascular or kidney disease — about 85%: In line with the trial overall
This group made up nearly the whole trial and produced nearly all its events.
People 60 and over with risk factors only — about 15%: Too few events to say anything
Not evidence of benefit or its absence. The trial was never sized to look here.
Whether people were already on insulin: Same direction in both
61% were, which is a marker of how advanced this population's diabetes was.
Where in the world people were enrolled: No clear differences across regions
Recruitment spanned 21 countries, though the event count in any one of them is small.

Clinical significance

For someone who cannot or will not inject, this is the trial establishing that the oral route is not a cardiovascular compromise. It should be read as safety rather than as an outcomes win. SOUL, the properly powered oral outcomes trial, is the one designed to answer superiority. A non-inferiority finding at 15.9 months also covers a shorter window than the multi-year trials it is often compared against.

Who sells semaglutide, and for how much

This trial tested Oral semaglutide (once daily, up to 14 mg). Across the 734 sellers on this register, 463 publish a standing monthly cash price for compounded semaglutide, from $47 a month, with a median of $174.

⛔ None of those sellers was in this trial. A compounded preparation is not the product studied here: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and its concentration is set by whichever pharmacy filled it. The result above is the strongest evidence available for semaglutide and it was generated on something else. Every seller, with its price record.

Frequently Asked Questions

On its primary endpoint — Cardiac death, a nonfatal heart attack, or a nonfatal stroke — whichever came first — the treatment arm recorded 61 of 1,591 (3.8%) against 76 of 1,592 (4.8%) for the comparator. Hazard ratio 0.79 (95% CI 0.57–1.11); P<0.001 for non-inferiority; P=0.17 for superiority. The trial cleared the bar it was built to clear: the tablet is not cardiovascularly worse than placebo. The 21% reduction in the point estimate is encouraging but did not reach significance (P=0.17 for superiority). The confidence interval crossed 1, and this trial was sized for safety on a short timeline, not to prove benefit.

3,183 participants, over Run until enough events accumulated rather than to a fixed date, giving a median 15.9 months, far shorter than the multi-year trials it gets compared against. It was a Phase 3a trial, finished; published June 2019. Registered as NCT02692716, which you can look up yourself rather than taking anyone's summary for it.

Adults with type 2 diabetes and an HbA1c of 7.0% or higher, entering either at 50 and over with established cardiovascular disease or reduced kidney function, or at 60 and over with risk factors alone. 84.7% arrived with established disease. Average age 66, 31.6% women, average BMI 32.3, average HbA1c 8.2%, and nearly 15 years since diagnosis. 61% were on insulin, a sign of advanced disease rather than a newly diagnosed population. ⚠ A trial result describes the population it was measured in. If you differ from it materially — in age, in baseline weight, in whether you have diabetes — the number is context rather than a prediction.

The most commonly reported were any serious adverse event (18.9% (301/1,591) against 22.5% (358/1,592) on comparator), stopped the drug over a side effect (11.6% against 6.5% (104/1,592) on comparator), nausea (Higher on oral semaglutide than placebo (consistent with the PIONEER program; specific incidence not the headline endpoint in the safety publication) against Lower (placebo rate similar to other GLP-1 CVOT placebo arms) on comparator). Lower on the drug than on placebo, mostly because a high-risk population had fewer cardiac events on it. Rates come from this trial's population under its own dose-escalation schedule; a faster or slower titration changes what people experience.

Secondary endpoints included death from a cardiac cause (15 of 1,591 (0.9%) against 30 of 1,592 (1.9%)); heart attacks that were not fatal (37 of 1,591 (2.3%) against 31 of 1,592 (1.9%)); strokes that were not fatal (12 of 1,591 (0.8%) against 16 of 1,592 (1.0%)). ⚠ Secondary endpoints are weaker evidence than the primary one — a trial is powered for its primary outcome, and the rest are read as supporting rather than as findings in their own right.

No, and this matters because the number gets used that way. PIONEER 6 tested Oral semaglutide (once daily, up to 14 mg) — the FDA-approved product, made by its manufacturer under Good Manufacturing Practice, at the doses and schedule the protocol specified. A compounded preparation of semaglutide is a different product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and its concentration is set by whichever pharmacy filled it. ⛔ A seller quoting this trial's result beside a compounded price is quoting evidence that was generated on something they are not selling. That is not the same as saying compounded semaglutide does not work — it is saying nobody measured it here.

It cannot tell you that. A trial reports an average across a defined population under a fixed protocol, with monitoring and adherence support most people do not get. It is the best evidence available and it is still a distribution rather than a promise — some participants lost far more than the mean and some lost nothing. What it is genuinely good for is comparing options against each other, which is what the rest of this section is for.

References

1.Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019. PMID: 31185157.
2.Novo Nordisk A/S. A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6) — Study Results. ClinicalTrials.gov, NCT02692716. 2019. https://clinicaltrials.gov/study/NCT02692716
3.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. PMID: 27633186.
4.Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. PMID: 27295427.
5.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131.
6.Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. PMID: 31189511.
7.U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets — Prescribing Information (initial approval September 2019). FDA Drug Label. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
8.McGuire DK, Marx N, Mulvagh SL, et al.; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. PMID: 40162642.
9.Novo Nordisk. Rybelsus and Ozempic (oral semaglutide) tablets — current US Prescribing Information (cardiovascular indication added October 2025). DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98